February 5, 2018 / 1:52 PM / 6 months ago

BRIEF-Corcept Therapeutics Receives Letter on saying Teva Pharmaceuticals USA Submitted An Abbreviated New Drug Application

Feb 5 (Reuters) - Corcept Therapeutics Inc:

* CORCEPT THERAPEUTICS - RECEIVED PARAGRAPH IV NOTICE LETTER ADVISING THAT TEVA PHARMACEUTICALS USA SUBMITTED AN ABBREVIATED NEW DRUG APPLICATION TO FDA

* CORCEPT THERAPEUTICS - TEVA PHARMA USA SUBMITTED ANDA SEEKING AUTHORIZATION TO MANUFACTURE, USE, SELL GENERIC VERSION OF KORLYM MIFEPRISTONE TABLETS IN U.S.

* CORCEPT THERAPEUTICS SAYS NOTICE LETTER ALLEGES THAT KORLYM PATENTS WILL NOT BE INFRINGED BY TEVA’S PROPOSED PRODUCT - SEC FILING Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below